Oncogenic kinases contribute to immunosuppression and modulate the tumor
microenvironment in solid tumors. Increasing evidence supports the fundamental role of …

Small-molecule kinase inhibitors have been well established and successfully developed in
the last decades for cancer target therapies. However, intrinsic or acquired drug resistance …

Simple Summary In this review, we evaluate the updated data of the immunological effects
of kinase inhibitors on the innate immune system and provide an in-depth analysis of the …

Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as
the standard of care for many types of cancer, but the strategies employed have continued to …

In recent years immune checkpoint inhibitors have garnered attention as being one of the
most promising types of immunotherapy on the horizon. There has been particular focus on …

Mechanistic insights of cancer immunology have led to the development of immune
checkpoint blockade therapy (ICBT), which has elicited a remarkable clinical response in …

Simple Summary Immune checkpoint inhibitors (ICIs) constitute a paradigm shift in cancer
therapy, and it has greatly expanded our knowledge of anticancer immunity and has …

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor
cell toxicity but also arises from the restoration of immunosurveillance, which has been …

Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the
treatment of advanced malignancies. Considering the remarkable efficacy of immune …

This review focuses on immune checkpoint inhibitors–immunomodulatory agents that aim to
relieve tumour-mediated immune-cell suppression. Immune checkpoint proteins can be …